Stanley Moore1, Hsin-Hsuan Juo1, Christoffer T Nielsen2, Helena Tyden3, Anders A Bengtsson3, Christian Lood4. 1. S. Moore, H.H. Juo, MD, C. Lood, PhD, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington, USA. 2. C.T. Nielsen, MD, PhD, Department of Autoimmunity and Biomarkers, Statens Serum Institut, Copenhagen, Denmark. 3. H. Tyden, MD, PhD, A.A. Bengtsson, MD, PhD, Division of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. 4. S. Moore, H.H. Juo, MD, C. Lood, PhD, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington, USA; Loodc@uw.edu.
Abstract
OBJECTIVE: Neutrophil extracellular traps (NET) are essential in host defense, but are also linked to inflammation and autoimmunity, including in systemic lupus erythematosus (SLE). We recently described that immune complexes (IC) induce NET formation, promoting SLE-like disease in mice. In the current study, we investigated, for the first time to our knowledge, the role of NET in human SLE and their association with disease activity and severity. METHODS: Levels of NET (myeloperoxidase-DNA complexes) were analyzed in plasma from 4 cross-sectional SLE cohorts (n = 44-142), 1 longitudinal SLE cohort (n = 47), and healthy individuals (n = 100) using ELISA. Type I interferon activity was determined using a cell reporter system. RESULTS: Patients with SLE had elevated levels of NET in circulation compared to healthy controls (p < 0.01). NET levels identified patients with a severe disease phenotype characterized by IC-driven nephritis (p < 0.05). Though not associated with current disease activity (p = 0.20), levels of NET were associated with future increase in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) within 3 months (OR 1.75, p = 0.01), as well as an overall heightened SLEDAI over 1 year (p < 0.01). Finally, levels of NET were associated with arterial events (OR 5.0, p = 0.02) and endothelial cell activation (p < 0.001). CONCLUSION: NET levels are elevated in patients with SLE, associated with IC-driven disease. NET levels provide significant clinical value in identifying patients at risk of active disease and/or severe disease, including nephritis and cardiovascular disease, and may allow for early interventions.
OBJECTIVE: Neutrophil extracellular traps (NET) are essential in host defense, but are also linked to inflammation and autoimmunity, including in systemic lupus erythematosus (SLE). We recently described that immune complexes (IC) induce NET formation, promoting SLE-like disease in mice. In the current study, we investigated, for the first time to our knowledge, the role of NET in humanSLE and their association with disease activity and severity. METHODS: Levels of NET (myeloperoxidase-DNA complexes) were analyzed in plasma from 4 cross-sectional SLE cohorts (n = 44-142), 1 longitudinal SLE cohort (n = 47), and healthy individuals (n = 100) using ELISA. Type I interferon activity was determined using a cell reporter system. RESULTS:Patients with SLE had elevated levels of NET in circulation compared to healthy controls (p < 0.01). NET levels identified patients with a severe disease phenotype characterized by IC-driven nephritis (p < 0.05). Though not associated with current disease activity (p = 0.20), levels of NET were associated with future increase in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) within 3 months (OR 1.75, p = 0.01), as well as an overall heightened SLEDAI over 1 year (p < 0.01). Finally, levels of NET were associated with arterial events (OR 5.0, p = 0.02) and endothelial cell activation (p < 0.001). CONCLUSION: NET levels are elevated in patients with SLE, associated with IC-driven disease. NET levels provide significant clinical value in identifying patients at risk of active disease and/or severe disease, including nephritis and cardiovascular disease, and may allow for early interventions.
Authors: Stephen R Clark; Adrienne C Ma; Samantha A Tavener; Braedon McDonald; Zahra Goodarzi; Margaret M Kelly; Kamala D Patel; Subhadeep Chakrabarti; Erin McAvoy; Gary D Sinclair; Elizabeth M Keys; Emma Allen-Vercoe; Rebekah Devinney; Christopher J Doig; Francis H Y Green; Paul Kubes Journal: Nat Med Date: 2007-03-25 Impact factor: 53.440
Authors: Jonatan Leffler; Myriam Martin; Birgitta Gullstrand; Helena Tydén; Christian Lood; Lennart Truedsson; Anders A Bengtsson; Anna M Blom Journal: J Immunol Date: 2012-02-17 Impact factor: 5.422
Authors: Rachael A Gordon; Jan M Herter; Florencia Rosetti; Allison M Campbell; Hiroshi Nishi; Michael Kashgarian; Sheldon I Bastacky; Anthony Marinov; Kevin M Nickerson; Tanya N Mayadas; Mark J Shlomchik Journal: JCI Insight Date: 2017-05-18
Authors: Jason S Knight; Wei Luo; Alexander A O'Dell; Srilakshmi Yalavarthi; Wenpu Zhao; Venkataraman Subramanian; Chiao Guo; Robert C Grenn; Paul R Thompson; Daniel T Eitzman; Mariana J Kaplan Journal: Circ Res Date: 2014-01-14 Impact factor: 17.367
Authors: Tineke Kraaij; Sylvia W A Kamerling; Esther N M de Rooij; Paul L A van Daele; Obbo W Bredewold; Jaap A Bakker; Ingeborg M Bajema; Hans U Scherer; Rene E M Toes; Tom J W Huizinga; Ton J Rabelink; Cees van Kooten; Y K Onno Teng Journal: J Autoimmun Date: 2018-04-07 Impact factor: 7.094
Authors: Helena Tydén; Christian Lood; Birgitta Gullstrand; Andreas Jönsen; Ola Nived; Gunnar Sturfelt; Lennart Truedsson; Fredrik Ivars; Tomas Leanderson; Anders A Bengtsson Journal: Rheumatology (Oxford) Date: 2013-08-13 Impact factor: 7.580
Authors: Christian Lood; Helena Tydén; Birgitta Gullstrand; Cecilia Klint; Christina Wenglén; Christoffer T Nielsen; Niels H H Heegaard; Andreas Jönsen; Robin Kahn; Anders A Bengtsson Journal: PLoS One Date: 2015-04-21 Impact factor: 3.240
Authors: Michele Compagno; Birgitta Gullstrand; Søren Jacobsen; Gro Ø Eilertsen; Jan Åke Nilsson; Christian Lood; Andreas Jönsen; Lennart Truedsson; Gunnar Sturfelt; Anders A Bengtsson Journal: Arthritis Res Ther Date: 2016-02-10 Impact factor: 5.156
Authors: Despina Michailidou; Bhargavi Duvvuri; Runa Kuley; David Cuthbertson; Peter C Grayson; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry W Moreland; Christian Pagnoux; Philip Seo; Ulrich Specks; Antoine G Sreih; Kenneth J Warrington; Tomas Mustelin; Paul A Monach; Peter A Merkel; Christian Lood Journal: Arthritis Res Ther Date: 2022-06-29 Impact factor: 5.606
Authors: D Vedder; M Gerritsen; B Duvvuri; R F van Vollenhoven; M T Nurmohamed; C Lood Journal: Arthritis Res Ther Date: 2020-06-18 Impact factor: 5.156
Authors: Christian Lood; Tomas Mustelin; Kennedy C Ukadike; Kathryn Ni; Xiaoxing Wang; Martin S Taylor; John LaCava; Lauren M Pachman; Mary Eckert; Anne Stevens Journal: Arthritis Res Ther Date: 2021-05-29 Impact factor: 5.156